Regional cerebral blood flow in Alzheimer's disease: Comparison between short and long-term donepezil therapy

Annals of Nuclear Medicine

Volumn 20, Issue 6, 2006, Pages 425-429

  Ushijima, Yo ^a,c   Okuyama, Chio ^a   Mori, Satoru ^b   Kubota, Takao ^a   Nakai, Takako ^a   Nishimura, Tsunehiko ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b MATSUSHITA MEMORIAL HOSPITAL   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Alzheimer's disease; Cerebral blood flow; Donepezil

Indexed keywords

CHOLINESTERASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DONEPEZIL; IOFETAMINE I 123;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTORADIOGRAPHY; BLOOD FLOWMETRY; BRAIN BLOOD FLOW; BRAIN CORTEX; CEREBELLUM; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; FRONTAL LOBE; HUMAN; INTERMETHOD COMPARISON; LONG TERM CARE; NERVE CONDUCTION; OUTCOME ASSESSMENT; PARIETAL LOBE; PRIORITY JOURNAL; SHORT COURSE THERAPY; TEMPORAL LOBE; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; CEREBROVASCULAR CIRCULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; NOOTROPIC AGENTS; PIPERIDINES; TREATMENT OUTCOME;

EID: 33747476814     PISSN: 09147187     EISSN: 09147187     Source Type: Journal    
DOI: 10.1007/BF03027378     Document Type: Article

References (18)

1. Kasa P, Papp H, Kasa P Jr, Torok I. Donepezil dose-dependently inhibits acetylcholinesterase activity in various areas and in the presynaptic cholinergic and the postsynaptic cholinoceptive enzyme-positive structures in the human and rat brain. Neuroscience 2000; 101: 89-100.
2. Kaasinen V, Nagren K, Jarvenpaa T, Roivainen A, Yu M, Oikonen V, et al. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J Clin Psychopharmacol 2002; 22: 615-620.
3. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50: 136-145.
4. Ceravolo R, Volterrani D, Tognoni G, Dell'Agnello G, Manca G, Kiferle L, et al. Cerebral perfusional effects of cholinesterase inhibitors in Alzheimer disease. Clin Neuropharmacol 2004; 27: 166-170.
5. Nakano S, Asada T, Matsuda H, Uno M, Takasaki M. Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. J Nucl Med 2001; 42: 1441-1445.
6. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Washington, DC; American Psychiatric Association, 1994: 123-163.
7. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA working group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
8. Iida H, Itoh H, Nakazawa M, Hatazawa J, Nishimura H, Onishi Y, et al. Quantitative mapping of regional cerebral blood flow using iodine-123-IMP and SPECT. J Nucl Med 1994; 35: 2019-2030.
9. Ichihara T, Ogawa K, Motomura N, Kubo A, Hashimoto S. Compton scatter compensation using the triple-energy window method for single- and dual-isotope SPECT. J Nucl Med 1993; 34: 2216-2221.
10. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995; 36: 1238-1248.
11. Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med 1994; 35: 1528-1537.
12. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981; 10: 122-126.
13. Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K. Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds. J Med Chem 1995; 38: 4821-4829.
14. Homma A, Takeda M, Imai Y, Udaka F, Hasegawa K, Kameyama M, et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord 2000; 11: 299-313.
15. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237-244.
16. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998; 8: 67-75.
17. Nobili F, Koulibaly M, Vitali P, Migneco O, Mariani G, Ebmeier K, et al. Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors. J Nucl Med 2002; 43: 983-990.
18. Staff RT, Gemmell HG, Shanks MF, Murray AD, Venneri A. Changes in the rCBF images of patients with Alzheimer's disease receiving Donepezil therapy. Nucl Med Commun 2000; 21: 37-41.